Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

Safety and Efficacy of OXB-202, a Genetically Engineered

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
georgejjl Member Profile
 
Followed By 77
Posts 11,110
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
georgejjl   Saturday, 12/15/18 05:09:10 PM
Re: None
Post # of 749 
Safety and Efficacy of OXB-202, a Genetically Engineered Tissue Therapy for the Prevention of Rejection in High-Risk Corneal Transplant Patients.
Fouladi N1, Parker M2, Kennedy V1, Binley K1, McCloskey L1, Loader J1, Kelleher M1, Mitrophanous KA1, Stout JT3, Ellis S1.
Author information
1
1 Oxford BioMedica (UK) Ltd. , Oxford, United Kingdom .
2
2 Casey Eye Institute, Oregon Health and Sciences University , Portland, Oregon.
3
3 Cullen Eye Institute, Baylor College of Medicine , Houston, Texas.
Abstract
Due to both the avascularity of the cornea and the relatively immune-privileged status of the eye, corneal transplantation is one of the most successful clinical transplant procedures. However, in high-risk patients, which account for >20% of the 180,000 transplants carried out worldwide each year, the rejection rate is high due to vascularization of the recipient cornea. The main reason for graft failure is irreversible immunological rejection, and it is therefore unsurprising that neovascularization (NV; both pre and post grafting) is a significant risk factor for subsequent graft failure. NV is thus an attractive target to prevent corneal graft rejection. OXB-202 (previously known as EncorStat®) is a donor cornea modified prior to transplant by ex vivo genetic modification with genes encoding secretable forms of the angiostatic human proteins, endostatin and angiostatin. This is achieved using a lentiviral vector derived from the equine infectious anemia virus called pONYK1EiA, which subsequently prevents rejection by suppressing NV. Previously, it has been shown that rabbit donor corneas treated with pONYK1EiA substantially suppress corneal NV, opacity, and subsequent rejection in an aggressive rabbit model of cornea graft rejection. Here, efficacy data are presented in a second rabbit model, which more closely mirrors the clinical setting for high-risk corneal transplant patients, and safety data from a 3-month good laboratory practice toxicology and biodistribution study of pONYK1EiA-modified rabbit corneas in a rabbit corneal transplant model. It is shown that pONYK1EiA-modified rabbit corneas (OXB-202) significantly reduce corneal NV and the rate of corneal rejection in a dose-dependent fashion, and are tolerated with no adverse toxicological findings or significant biodistribution up to 13 weeks post surgery in these rabbit studies. In conclusion, angiogenesis is a valid target to prevent corneal graft rejection in a high-risk setting, and transplanted genetically modified corneas are safe and well-tolerated in an animal model. These data support the evaluation of OXB-202 in a first-in-human trial.

https://www.ncbi.nlm.nih.gov/pubmed/29361840

Good luck and GOD bless,

George

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist